Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor

Immunological Investigations

Volumn 40, Issue 4, 2011, Pages 383-399

  Park, You Soo ^a,b   Bae, Jae Ho ^a   Son, Cheol Hun ^b   Lee, Kyung Soo ^b   Kim, Wontaek ^c   Jung, Min Ho ^d   Yang, Kwangmo ^e   Kim, Sun Hee ^a   Kang, Chi Dug ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Binex Co Ltd   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Dong A University   (South Korea)

^e Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Cancer immunotherapy; Cyclophosphamide; Dendritic cells; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; PICIBANIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; FEMALE; IMMUNIZATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; FEMALE; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED C3H; NEOPLASMS; RADIOIMMUNOTHERAPY; T-LYMPHOCYTES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953796797     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.552141     Document Type: Article

References (58)

1. Asavaroengchai, W., Kotera, Y., Mule, J. J. (2002). Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99:931-936. (Pubitemid 34106613)
2. Askenase, P. W., Hayden, B. J., Gershon, R. K. (1975). Augmentation of delayedtype hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med. 141:697-702.
3. Banchereau, J., Palucka, A. K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306. (Pubitemid 40516155)
4. Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M., Dhodapkar, K. M. (2006). Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108:2655-2661.
5. Berd, D., Maguire, H. C., Jr., Mastrangelo, M. J. (1986). Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:2572-2577. (Pubitemid 16120733)
6. Berd, D., Mastrangelo, M. J. (1988). Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 48:1671-1675. (Pubitemid 18091225)
7. Boissier, M. C., Assier, E., Biton, J., Denys, A., Falgarone, G., Bessis, N. (2009). Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 76:10-14.
8. Bracci, L., Moschella, F., Sestili, P., La Sorsa, V., Valentini, M., Canini, I., Baccarini, S., Maccari, S., Ramoni, C., Belardelli, F., and others (2007). Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13:644-653. (Pubitemid 46225372)
9. Campbell, D. J., Ziegler, S. F. (2007). FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat. Rev. Immunol. 7:305-310. (Pubitemid 46480960)
10. + regulatory T cells. Cell. Biol. Int. 33:565-571.
11. Chi, K. H., Liu, S. J., Li, C. P., Kuo, H. P., Wang, Y. S., Chao, Y., Hsieh, S. L. (2005). Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28: 129-135. (Pubitemid 40328199)
12. Cools, N., Ponsaerts, P., Van Tendeloo, V. F., Berneman, Z. N. (2007). Regulatory T cells and human disease. Clin. Dev. Immunol. 2007:891-895.
13. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., and others (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949. (Pubitemid 39273735)
14. Davis, I. D., Jefford, M., Parente, P., Cebon, J. (2003). Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73:3-9.
15. Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., Formenti, S. C. (2004). Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58: 862-870. (Pubitemid 38221143)
16. Fong, L. E. E. (2000). Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol 18:245-273.
17. Formenti, S. C., Demaria, S. (2008). Local control by radiotherapy: Is that all there is? Breast Cancer Res. 10:215.
18. Formenti, S. C., Demaria, S. (2009). Systemic effects of local radiotherapy. Lancet Oncol. 10:718-726.
19. Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., Chauffert, B. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56:641-648. (Pubitemid 46348738)
20. Gilboa, E., Nair, S. K., Lyerly, H. K. (1998). Immunotherapy of cancer with dendriticcell- based vaccines. Cancer Immunol. Immunother. 46:82-87. (Pubitemid 28177482)
21. Gochi, A., Orita, K., Fuchimoto, S., Tanaka, N., Ogawa, N. (2001). The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br. J. Cancer 84:443-451. (Pubitemid 32215867)
22. Hegde, U., Chhabra, A., Chattopadhyay, S., Das, R., Ray, S., Chakraborty, N. G. (2008). Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology 75:200-208.
23. Holtl, L., Ramoner, R., Zelle-Rieser, C., Gander, H., Putz, T., Papesh, C., Nussbaumer, W., Falkensammer, C., Bartsch, G., Thurnher, M. (2005). Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol. Immunother. 54:663-670. (Pubitemid 40884162)
24. Hoon, D. S., Foshag, L. J., Nizze, A. S., Bohman, R., Morton, D. L. (1990). Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 50:5358-5364. (Pubitemid 20302988)
25. Huang, J., Wang, Y., Guo, J., Lu, H., Lin, X., Ma, L., Teitz-Tennenbaum, S., Chang, A. E., Li, Q. (2007). Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression. Clin. Immunol. 123:298-310. (Pubitemid 46818127)
26. Itoh, T., Ueda, Y., Okugawa, K., Fujiwara, H., Fuji, N., Yamashita, T., Fujiki, H., Harada, S., Yoshimura, T., Yamagishi, H (2003). Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol. Immunother. 52:207-214. (Pubitemid 36535280)
27. Kikkawa, F., Kawai, M., Oguchi, H., Kojima, M., Ishikawa, H., Iwata, M., Maeda, O., Tomoda, Y., Arii, Y., Kuzuya, K., and others (1993) Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur. J. Cancer 29A:1542-1546. (Pubitemid 23251794)
28. Kim, K. W. K. S., Shin, J. G., et al. (2004). Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. I. J. Cancer 109: 685-690.
29. Kuroki, H., Morisaki, T., Matsumoto, K., Onishi, H., Baba, E., Tanaka, M., Katano, M. (2003). Streptococcal preparation OK-432: A new maturation factor of monocytederived dendritic cells for clinical use. Cancer Immunol. Immunother. 52:561-568. (Pubitemid 37056131)
30. Lissoni, P., Brivio, F., Fumagalli, L., Messina, G., Meregalli, S., Porro, G., Rovelli, F., Vigore, L., Tisi, E., D'Amico, G. (2009). Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 29:1847-1852.
31. Liu, J. Y., Wu, Y., Zhang, X. S., Yang, J. L., Li, H. L., Mao, Y. Q., Wang, Y., Cheng, X., Li, Y. Q., Xia, J. C., and others (2007). Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol. Immunother. 56:1597-1604. (Pubitemid 47094389)
32. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., and others (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2756-2761. (Pubitemid 34921025)
33. Lizee, G., Radvanyi, L. G., Overwijk, W. W., Hwu, P. (2006). Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 12:4794-4803. (Pubitemid 44338563)
34. Lutsiak, M. E., Semnani, R. T., De Pascalis, R., Kashmiri, S. V., Schlom, J., Sabzevari, H. (2005). Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868. (Pubitemid 40446280)
35. Machiels, J. P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., Jaffee, E. M. (2001). Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3689-3697. (Pubitemid 32694981)
36. Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S., Polansky, J. K., MacIsaac, K. D., Levine, S. S., Fraenkel, E., von Boehmer, H., Young, R. A. (2007). Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445:931-935.
37. Mitsuoka, A., Baba, M., Morikawa, S. (1976). Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature 262: 77-78.
38. Motoyoshi, Y., Kaminoda, K., Saitoh, O., Hamasaki, K., Nakao, K., Ishii, N., Nagayama, Y., Eguchi, K (2006). Different mechanisms for anti-tumor effects of low- and highdose cyclophosphamide. Oncol. Rep. 16:141-146.
39. Nakahara, S., Tsunoda, T., Baba, T., Asabe, S., Tahara, H. (2003). Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63:4112-4118. (Pubitemid 36917935)
40. Nakai, N., Katoh, N., Kitagawa, T., Ueda, E., Takenaka, H., Kishimoto, S. (2009). Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J. Dermatol. Sci. 54:31-37.
41. Nakamura, K., Kitani, A., Strober, W. (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194:629-644. (Pubitemid 32844773)
42. Nencioni, A., Brossart, P. (2004). Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22:501-13. (Pubitemid 39014566)
43. Okamoto, M., Furuichi, S., Nishioka, Y., Oshikawa, T., Tano, T., Ahmed, S. U., Takeda, K., Akira, S., Ryoma, Y., Moriya, Y., and others (2004). Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cellbased immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 64:5461-5470. (Pubitemid 39006570)
44. Ono, T., Harada, M., Yamada, A., Tanaka, M., Takao, Y., Tanaka, Y., Mine, T., Sakamoto, K., Nakashima, T., Itoh, K. (2006). Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin. Cancer Res. 12:1325-1332. (Pubitemid 43342525)
45. Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., Wansley, E. K., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., and others (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203:1259-1271. (Pubitemid 43736595)
46. Schmidtner, J., Distel, L. V., Ott, O. J., Nkenke, E., Sprung, C. N., Fietkau, R., Lubgan, D. (2009). Hyperthermia and irradiation of head and neck squamous cancer cells causes migratory profile changes of tumour infiltrating lymphocytes. Int. J. Hyperthermia 25:347-354.
47. Smyth, M. J., Cretney, E., Kershaw, M. H., Hayakawa, Y. (2004) Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202:275-293. (Pubitemid 39576919)
48. Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Menard, C., Ghiringhelli,F., Terme, M., Carpentier, A. F., Darrasse-Jeze, G., and others (2006). Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176:2722-2729.
49. Teitz-Tennenbaum, S., Li, Q., Rynkiewicz, S., Ito, F., Davis,M. A., McGinn, C. J., Chang, A. E. (2003). Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 63:8466-8475. (Pubitemid 37549503)
50. van der Vliet, H. J., Koon, H. B., Atkins, M. B., Balk, S. P., Exley,M. A. (2007) Exploiting regulatory T-cell populations for the immunotherapy of cancer. J. Immunother. 30:591-595. (Pubitemid 47229693)
51. Vierboom, M. P., Bos, G. M., Ooms, M., Offringa, R., Melief, C. J. (2000). Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer 87:253-260. (Pubitemid 30434355)
52. Vignali, D. A., Collison, L. W., Workman, C. J. (2008). How regulatory T cells work. Nat Rev Immunol. 8:523-532.
53. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., Ferradini, L. (2004). Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173:1444-1453. (Pubitemid 38924326)
54. Watanabe, Y., Iwa, T. (1987). Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J. Biol. Response Mod. 6: 169-180. (Pubitemid 17058392)
55. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., June, C. H. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766-4772. (Pubitemid 32691889)
56. Yokokawa, J., Cereda, V., Remondo, C., Gulley, J. L., Arlen, P. M., Schlom, J., Tsang, K. Y. (2008). Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin. Cancer Res. 14: 1032-1040. (Pubitemid 351302548)
57. Zanoni, I., Granucci, F., Foti, M., Ricciardi-Castagnoli, P. (2007). Self-tolerance, dendritic cell (DC)-mediated activation and tissue distribution of natural killer (NK) cells. Immunol. Lett. 110:6-17. (Pubitemid 46678227)
58. Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6:295-307.